Indivior PLC (INDV)
NASDAQ: INDV · Real-Time Price · USD
24.98
+0.25 (1.01%)
At close: Sep 5, 2025, 4:00 PM
25.24
+0.26 (1.04%)
After-hours: Sep 5, 2025, 7:24 PM EDT

Company Description

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.

The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD).

The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Indivior PLC
Indivior logo
CountryUnited States
Founded1994
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees1,051
CEOJoseph Ciaffoni

Contact Details

Address:
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
United States
Phone804 379 1090
Websiteindivior.com

Stock Details

Ticker SymbolINDV
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001625297
ISIN NumberGB00BN4HT335
SIC Code2834

Key Executives

NamePosition
Joseph J. CiaffoniChief Executive Officer and Director
Ryan PreblickChief Financial Officer
Vishal KaliaChief Strategy and Operating Officer
Dr. Christian HeidbrederChief Scientific Officer
Jason ThompsonVice President of Investor Relations
Cynthia CetaniChief Integrity and Compliance Officer
Jeffrey W. Burris J.D.Chief Legal Officer
Angela Colon-Mahoney M.S.Chief Human Resources Officer
Hillel WestChief Manufacturing and Supply Officer
Patrick A. BarryChief Commercial Officer

Latest SEC Filings

DateTypeTitle
Sep 5, 2025SCHEDULE 13D/AFiling
Sep 4, 2025144Filing
Aug 28, 2025144Filing
Aug 26, 20258-KCurrent Report
Aug 22, 20258-KCurrent Report
Aug 13, 2025SCHEDULE 13G/AFiling
Aug 4, 20258-K/A[Amend] Current report
Jul 31, 202510-QQuarterly Report
Jul 31, 20258-KCurrent Report
Jul 29, 2025SCHEDULE 13D/AFiling